CPC Scientific, a premier peptide and oligonucleotide-focused CRDMO and a wholly owned subsidiary of Medtide Inc. (HKEX: 3880.HK), today announced that its Hangzhou-based CGMP manufacturing facility, Chinese Peptide Company, has successfully completed the Drug Master File (DMF) filing for its self-developed Tirzepatide active pharmaceutical ingredient (API) with the U.S. Food and Drug Administration (FDA) under DMF number 043979.
Teduglutide is a peptide made up of 33 amino acids. It differs from GLP-2 by one amino acid (A to G), which makes it more resistant to dipeptidyl peptidase-4 proteolysis, giving it a longer half-life as compared to endogenous GLP-2. FDA approved on December 21, 2012.
This presentation will focus on the development of the latest GLP-1 mimetics and GLP-1/GIP dual agonists, with unparalleled efficacy and ease of delivery.
SAN JOSE, CA., June 25, 2020 /CPCNewswire/ — CPC Scientific Inc., a San Jose based CDMO with GMP manufacturing facilities in Hangzhou, is pleased to announce that their drug master file (DMF) for cetrorelix acetate has been submitted to the U.S. Food and Drug Administration and has been issued DMF# 034884. This generic peptide API […]
We are very excited about the addition of the cetrorelix DMF to our growing generic peptide portfolio. Our multi-kg scale cGMP manufacturing facility for cetrorelix will provide more opportunities for IVF treatments in the medical communities and pathways to new treatments for hormone-sensitive breast and prostate cancers.
